Weekly Recap: LX2006 on track, topline 2027 and Apertura TfR1 CapX CNS

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is positioning LX2006 for an H2 2027 pivotal readout with cash into 2028 while adding Mantle Therapeutics’ fragile-aging CNS programs and an Apertura Gene Therapy TfR1 CapX AAV capsid deal to bolster IV CNS delivery for its Friedreich ataxia program.Previous W…